Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Enrico Caserta, Junie Chea, Megan Minnix, Domenico Viola, Steven Vonderfecht, Paul Yazaki, Desiree Crow, Jihane Khalife, James F. Sanchez, Joycelynne M. Palmer, Susanta Hui, Nadia Carlesso, Jonathan Keats, Young Kim, Ralf Buettner, Guido Marcucci, Steven Rosen, John Shively, David Colcher, Amrita Krishnan & 1 others Flavia Pichiorri

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on developing novel diagnostic criteria to also account for disease dissemination. Positron emission tomography/computed tomography (PET/CT) is often used as a noninvasive monitoring strategy to assess cancer cell dissemination, but because the uptake of the currently used radiotracer 18fluorodeoxyglucose (18F-FDG) is a function of the metabolic activity of both malignant and nonmalignant cells, the results frequently lack sufficient specificity. Radiolabeled antibodies targeting MM tissue may detect disease irrespective of cell metabolism. Hence, we conjugated the clinically significant CD38-directed human antibody daratumumab (Darzalex [Dara]) to the DOTA chelator and labeled it with the positron-emitting radionuclide copper 64 (64Cu; 64Cu-DOTA-Dara). Here, we show that 64Cu-DOTA-Dara can efficiently bind CD38 on the surface ofMMcells and was mainly detected in the bones associated with tumor in a MM murine model. We also show that PET/CT based on 64Cu-DOTA-Dara displays a higher resolution and specificity to detectMMcell dissemination than does 18F-FDG PET/CT and was even more sensitive than were bioluminescence signals. We therefore have supporting evidence for using 64Cu-DOTA-Dara as a novel imaging agent for MM.

Original languageEnglish (US)
Pages (from-to)741-745
Number of pages5
JournalBlood
Volume131
Issue number7
DOIs
StatePublished - Feb 15 2018
Externally publishedYes

Fingerprint

Positron emission tomography
Multiple Myeloma
Tomography
Copper
Imaging techniques
Fluorodeoxyglucose F18
Bioluminescence
Antibodies
Positrons
Chelating Agents
Metabolism
Radioisotopes
daratumumab
Positron Emission Tomography Computed Tomography
Tumors
Neoplasms
Bone
Cells
Electrons
Tissue

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Caserta, E., Chea, J., Minnix, M., Viola, D., Vonderfecht, S., Yazaki, P., ... Pichiorri, F. (2018). Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood, 131(7), 741-745. https://doi.org/10.1182/blood-2017-09-807263

Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. / Caserta, Enrico; Chea, Junie; Minnix, Megan; Viola, Domenico; Vonderfecht, Steven; Yazaki, Paul; Crow, Desiree; Khalife, Jihane; Sanchez, James F.; Palmer, Joycelynne M.; Hui, Susanta; Carlesso, Nadia; Keats, Jonathan; Kim, Young; Buettner, Ralf; Marcucci, Guido; Rosen, Steven; Shively, John; Colcher, David; Krishnan, Amrita; Pichiorri, Flavia.

In: Blood, Vol. 131, No. 7, 15.02.2018, p. 741-745.

Research output: Contribution to journalArticle

Caserta, E, Chea, J, Minnix, M, Viola, D, Vonderfecht, S, Yazaki, P, Crow, D, Khalife, J, Sanchez, JF, Palmer, JM, Hui, S, Carlesso, N, Keats, J, Kim, Y, Buettner, R, Marcucci, G, Rosen, S, Shively, J, Colcher, D, Krishnan, A & Pichiorri, F 2018, 'Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma', Blood, vol. 131, no. 7, pp. 741-745. https://doi.org/10.1182/blood-2017-09-807263
Caserta E, Chea J, Minnix M, Viola D, Vonderfecht S, Yazaki P et al. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood. 2018 Feb 15;131(7):741-745. https://doi.org/10.1182/blood-2017-09-807263
Caserta, Enrico ; Chea, Junie ; Minnix, Megan ; Viola, Domenico ; Vonderfecht, Steven ; Yazaki, Paul ; Crow, Desiree ; Khalife, Jihane ; Sanchez, James F. ; Palmer, Joycelynne M. ; Hui, Susanta ; Carlesso, Nadia ; Keats, Jonathan ; Kim, Young ; Buettner, Ralf ; Marcucci, Guido ; Rosen, Steven ; Shively, John ; Colcher, David ; Krishnan, Amrita ; Pichiorri, Flavia. / Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. In: Blood. 2018 ; Vol. 131, No. 7. pp. 741-745.
@article{d6e10e36652f44c69b79912c335f4504,
title = "Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma",
abstract = "As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on developing novel diagnostic criteria to also account for disease dissemination. Positron emission tomography/computed tomography (PET/CT) is often used as a noninvasive monitoring strategy to assess cancer cell dissemination, but because the uptake of the currently used radiotracer 18fluorodeoxyglucose (18F-FDG) is a function of the metabolic activity of both malignant and nonmalignant cells, the results frequently lack sufficient specificity. Radiolabeled antibodies targeting MM tissue may detect disease irrespective of cell metabolism. Hence, we conjugated the clinically significant CD38-directed human antibody daratumumab (Darzalex [Dara]) to the DOTA chelator and labeled it with the positron-emitting radionuclide copper 64 (64Cu; 64Cu-DOTA-Dara). Here, we show that 64Cu-DOTA-Dara can efficiently bind CD38 on the surface ofMMcells and was mainly detected in the bones associated with tumor in a MM murine model. We also show that PET/CT based on 64Cu-DOTA-Dara displays a higher resolution and specificity to detectMMcell dissemination than does 18F-FDG PET/CT and was even more sensitive than were bioluminescence signals. We therefore have supporting evidence for using 64Cu-DOTA-Dara as a novel imaging agent for MM.",
author = "Enrico Caserta and Junie Chea and Megan Minnix and Domenico Viola and Steven Vonderfecht and Paul Yazaki and Desiree Crow and Jihane Khalife and Sanchez, {James F.} and Palmer, {Joycelynne M.} and Susanta Hui and Nadia Carlesso and Jonathan Keats and Young Kim and Ralf Buettner and Guido Marcucci and Steven Rosen and John Shively and David Colcher and Amrita Krishnan and Flavia Pichiorri",
year = "2018",
month = "2",
day = "15",
doi = "10.1182/blood-2017-09-807263",
language = "English (US)",
volume = "131",
pages = "741--745",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

AU - Caserta, Enrico

AU - Chea, Junie

AU - Minnix, Megan

AU - Viola, Domenico

AU - Vonderfecht, Steven

AU - Yazaki, Paul

AU - Crow, Desiree

AU - Khalife, Jihane

AU - Sanchez, James F.

AU - Palmer, Joycelynne M.

AU - Hui, Susanta

AU - Carlesso, Nadia

AU - Keats, Jonathan

AU - Kim, Young

AU - Buettner, Ralf

AU - Marcucci, Guido

AU - Rosen, Steven

AU - Shively, John

AU - Colcher, David

AU - Krishnan, Amrita

AU - Pichiorri, Flavia

PY - 2018/2/15

Y1 - 2018/2/15

N2 - As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on developing novel diagnostic criteria to also account for disease dissemination. Positron emission tomography/computed tomography (PET/CT) is often used as a noninvasive monitoring strategy to assess cancer cell dissemination, but because the uptake of the currently used radiotracer 18fluorodeoxyglucose (18F-FDG) is a function of the metabolic activity of both malignant and nonmalignant cells, the results frequently lack sufficient specificity. Radiolabeled antibodies targeting MM tissue may detect disease irrespective of cell metabolism. Hence, we conjugated the clinically significant CD38-directed human antibody daratumumab (Darzalex [Dara]) to the DOTA chelator and labeled it with the positron-emitting radionuclide copper 64 (64Cu; 64Cu-DOTA-Dara). Here, we show that 64Cu-DOTA-Dara can efficiently bind CD38 on the surface ofMMcells and was mainly detected in the bones associated with tumor in a MM murine model. We also show that PET/CT based on 64Cu-DOTA-Dara displays a higher resolution and specificity to detectMMcell dissemination than does 18F-FDG PET/CT and was even more sensitive than were bioluminescence signals. We therefore have supporting evidence for using 64Cu-DOTA-Dara as a novel imaging agent for MM.

AB - As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on developing novel diagnostic criteria to also account for disease dissemination. Positron emission tomography/computed tomography (PET/CT) is often used as a noninvasive monitoring strategy to assess cancer cell dissemination, but because the uptake of the currently used radiotracer 18fluorodeoxyglucose (18F-FDG) is a function of the metabolic activity of both malignant and nonmalignant cells, the results frequently lack sufficient specificity. Radiolabeled antibodies targeting MM tissue may detect disease irrespective of cell metabolism. Hence, we conjugated the clinically significant CD38-directed human antibody daratumumab (Darzalex [Dara]) to the DOTA chelator and labeled it with the positron-emitting radionuclide copper 64 (64Cu; 64Cu-DOTA-Dara). Here, we show that 64Cu-DOTA-Dara can efficiently bind CD38 on the surface ofMMcells and was mainly detected in the bones associated with tumor in a MM murine model. We also show that PET/CT based on 64Cu-DOTA-Dara displays a higher resolution and specificity to detectMMcell dissemination than does 18F-FDG PET/CT and was even more sensitive than were bioluminescence signals. We therefore have supporting evidence for using 64Cu-DOTA-Dara as a novel imaging agent for MM.

UR - http://www.scopus.com/inward/record.url?scp=85042195723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042195723&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-09-807263

DO - 10.1182/blood-2017-09-807263

M3 - Article

VL - 131

SP - 741

EP - 745

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -